Gilead CEO Takes Aim at Medicare Pricing: 'Pill Penalty' Threatens Drug Innovation
Gilead stock rose after Q3 earnings beat Wall Street estimates and strong HIV drug demand prompted an increased 2026 sales forecast.
Stocks · News reference
Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday
Analysts raised targets for Cheniere and Incyte, while cutting Stryker, Roblox, Intel and Honeywell; Bright Horizons was downgraded.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Citizens Maintains Market Outperform on Amazon.com, Lowers Price Target to $275
Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Trade Mixed as AMZN, INTC Slide After Q3 Earnings—DELL, LLY, AZN in Focus (UPDATED)
U.S. stock were mixed on Friday, as the Dow Jones, S&P 500, and Nasdaq 100 index futures moved in different direction.
Evercore ISI Group Maintains Outperform on Stryker, Lowers Price Target to $320
Evercore ISI Group Maintains In-Line on Incyte, Raises Price Target to $127
Evercore ISI Group Maintains Outperform on Intel, Lowers Price Target to $131